BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.5K Targets. Of those, 1.6M data for 765K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

33 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Cmpds
Data
Article Title
Organization
18
Quinoxaline N-oxide containing potent angiotensin II receptor antagonists: synthesis, biological properties, and structure-activity relationships.EBI
Bristol Myers Squibb
45
Nonpeptide angiotensin II receptor antagonists. 2. Design, synthesis, and structure-activity relationships of 2-alkyl-4-(1H-pyrrol-1-yl)-1H-imidazole derivatives: profile of 2-propyl-1-[[2'-(1H-tetrazol-5-yl)-[1,1' -biphenyl]-4-yl]-methyl]-4-[2-(trifluoroacetyl)-1H-pyrrol-1-yl]-1H- imidazole-5-carEBI
Warner-Lambert
98
Synthesis and structure-activity relationships of a novel series of non-peptide angiotensin II receptor binding inhibitors specific for the AT2 subtype.EBI
Warner-Lambert
27
 
4,5-Dihydro-4-oxo-3H-imidazo[4,5-c]pyridines: potent arylacetic acid-derived AT1 antagonists with improved affinity for the AT2 receptorEBI
TBA
21
 
Balanced AT1 and AT2 angiotensin II antagonists. II. Potent 5 α-hydroxyacid imidazolyl biphenyl sulfonylureasEBI
TBA
39
 
The SAR of 6-(N-alkyl-N-acyl)-2-propyl-3-[(2′-tetrazol-5-yl)biphen-4-yl)methyl]-quinazolinones as balanced affinity antagonists of the human AT1 and AT2 receptorsEBI
TBA
18
 
Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the AT1 and AT2 subtypesEBI
TBA
23
 
Development of angiotensin II antagonists with equipotent affinity for human AT1 and AT2 receptor subtypes.EBI
TBA
23
 
Balanced angiotensin II receptor antagonists. I. The effects of biphenyl “ortho”-substitution on AT1/AT2 affinitiesEBI
TBA
25
Discovery of 4'-[(imidazol-1-yl)methyl]biphenyl-2-sulfonamides as dual endothelin/angiotensin II receptor antagonists.EBI
Bristol Myers Squibb
24
Multiple binding modes for the receptor-bound conformations of cyclic AII agonists.EBI
Washington University
22
A novel series of selective, non-peptide inhibitors of angiotensin II binding to the AT2 site.EBI
Dupont Pharmaceuticals
44
Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.EBI
University of Innsbruck
1
Bicyclic tripeptide mimetics with reverse turn inducing properties.EBI
Uppsala University
7
Angiotensin II analogues encompassing 5,9- and 5,10-fused thiazabicycloalkane tripeptide mimetics.EBI
Uppsala University
5
Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group.EBI
Wyeth-Ayerst Research
9
Design, synthesis, and biological activities of four angiotensin II receptor ligands with gamma-turn mimetics replacing amino acid residues 3-5.EBI
Uppsala University
35
4-Diazinyl- and 4-pyridinylimidazoles: potent angiotensin II antagonists. A study of their activity and computational characterization.EBI
Laboratori Guidotti
53
Sulfonylureas and sulfonylcarbamates as new non-tetrazole angiotensin II receptor antagonists. Discovery of a highly potent orally active (imidazolylbiphenylyl)sulfonylurea (HR 720).EBI
Hoechst Roussel Pgu Cardiovascular Agents
19
Pyrido[2,3-d]pyrimidine angiotensin II antagonists.EBI
Wyeth-Ayerst Research
16
Conformational restriction of angiotensin II: cyclic analogues having high potency.EBI
G.D. Searle And